These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1735852)

  • 41. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits.
    Sherman MP; Campbell LA; Merritt TA; Long WA; Gunkel JH; Curstedt T; Robertson B
    J Pediatr; 1994 Dec; 125(6 Pt 1):939-47. PubMed ID: 7996369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant.
    Bhutani VK; Abbasi S; Long WA; Gerdes JS
    J Pediatr; 1992 Feb; 120(2 Pt 2):S18-24. PubMed ID: 1735846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elastase activity and surfactant protein concentration in tracheal aspirates from neonates receiving synthetic surfactant.
    Gerdes J; Whitsett J; Long W
    J Pediatr; 1992 Feb; 120(2 Pt 2):S34-9. PubMed ID: 1735850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current surfactant use in premature infants.
    Suresh GK; Soll RF
    Clin Perinatol; 2001 Sep; 28(3):671-94. PubMed ID: 11570160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surfactant replacement therapy in neonates less than 32 weeks gestation: effect on neonatal intensive care resource utilization.
    Diwaker K; Roberts S; John E
    J Paediatr Child Health; 1993 Dec; 29(6):434-7. PubMed ID: 8286159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.
    Horbar JD; Wright LL; Soll RF; Wright EC; Fanaroff AA; Korones SB; Shankaran S; Oh W; Fletcher BD; Bauer CR
    J Pediatr; 1993 Nov; 123(5):757-66. PubMed ID: 8229487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant.
    Abbasi S; Bhutani VK; Gerdes JS
    J Pediatr; 1993 Mar; 122(3):446-52. PubMed ID: 8441104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health and neurodevelopmental outcome at 1-year adjusted age in 508 infants weighing 700 to 1100 grams who received prophylaxis with one versus three doses of synthetic surfactant. American Exosurf Neonatal Study Groups I and II.
    Gerdes J; Gerdes M; Beaumont E; Cook L; Dhanireddy R; Kopleman A; Jarret R; Long W
    J Pediatr; 1995 May; 126(5 Pt 2):S26-32. PubMed ID: 7745508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Criteria for use of colfosceril (Exosurf) in neonates.
    Bhatt-Mehta V; Schumacher RE
    Clin Pharm; 1992 Apr; 11(4):355-7. PubMed ID: 1563234
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity.
    Modanlou HD; Beharry K; Padilla G; Norris K; Safvati S; Aranda JV
    J Perinatol; 1997; 17(6):455-60. PubMed ID: 9447532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Colfosceril palmitate (Exosurf)--artificial surfactant for immature lungs.
    Drug Ther Bull; 1991 Jun; 29(12):46. PubMed ID: 1935584
    [No Abstract]   [Full Text] [Related]  

  • 52. Overview of clinical trials comparing natural and synthetic surfactants.
    Halliday HL
    Biol Neonate; 1995; 67 Suppl 1():32-47. PubMed ID: 7647157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with Exosurf.
    Hamdan AH; Shaw NJ
    Arch Dis Child Fetal Neonatal Ed; 1995 May; 72(3):F176-9. PubMed ID: 7796233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Energy expenditure during synthetic surfactant replacement therapy for neonatal respiratory distress syndrome.
    Hazan J; Chessex P; Piedboeuf B; Bourgeois M; Bard H; Long W
    J Pediatr; 1992 Feb; 120(2 Pt 2):S29-33. PubMed ID: 1735848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Static respiratory compliance in the newborn. III: Early changes after exogenous surfactant treatment.
    Stenson BJ; Glover RM; Parry GJ; Wilkie RA; Laing IA; Tarnow-Mordi WO
    Arch Dis Child Fetal Neonatal Ed; 1994 Jan; 70(1):F19-24. PubMed ID: 8117122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On surfactant replacement therapy with Exosurf.
    Courtney SE
    Pediatr Pulmonol; 1992 May; 13(1):60-1. PubMed ID: 1589317
    [No Abstract]   [Full Text] [Related]  

  • 57. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?
    Speer CP; Robertson B; Halliday HL
    Acta Paediatr; 2000 May; 89(5):510-2. PubMed ID: 10852182
    [No Abstract]   [Full Text] [Related]  

  • 58. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
    Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
    N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?
    Kukkonen AK; Virtanen M; Järvenpää AL; Pokela ML; Ikonen S; Fellman V
    Acta Paediatr; 2000 May; 89(5):556-61. PubMed ID: 10852192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lung function in prematurely delivered rabbits treated with a synthetic surfactant.
    Tooley WH; Clements JA; Muramatsu K; Brown CL; Schlueter MA
    Am Rev Respir Dis; 1987 Sep; 136(3):651-6. PubMed ID: 3307569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.